F2G Ltd Completes £5 million Financing Round To Fund Pre-Clinical And Clinical Development  
3/22/2006 2:44:13 PM

F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the completion of a £5 million equity financing round with an international syndicate of existing investors and a new investor, Astellas Venture Management LLC (USA), venture capital arm of Astellas Pharma Inc.